Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Psychopharmacology Psychedelic Drugs MDMA

New study suggests “comedowns” associated with MDMA are not a result of the drug itself

by Eric W. Dolan
April 22, 2022
in MDMA, Psychopharmacology
(Photo credit: DEA)

(Photo credit: DEA)

Share on TwitterShare on Facebook
Stay informed on the latest psychology and neuroscience research—follow PsyPost on LinkedIn for daily updates and insights.

The drug MDMA (3,4-methylenedioxymethamphetamine) might not produce depressive “comedowns” when used in a controlled clinical setting, according to new research published in the Journal of Psychopharmacology. The findings offer some initial evidence that declines in mood and cognition in the days following MDMA use are produced by factors related to recreational consumption, such as drug impurity.

MDMA, commonly known as “molly,” has shown promise in treating various mental health conditions when combined with psychotherapeutic interventions. But there are concerns about the after-effects of the drug, which have been widely reported by recreational users.

“Decreased mood or ‘comedowns’ have been commonly noted amongst recreational MDMA users. We hypothesized that these comedowns might be more related to the context that individuals take recreational MDMA in rather than due to MDMA itself,” said study author Jacob Aday, a postdoctoral scholar in the Translational Psychedelic Research Program at University of California, San Francisco.

“In other words, when people take ‘MDMA’ recreationally, it is often cut with other drugs by suppliers and combined with alcohol and other substances by users, dosages are highly variable, and it is regularly taken in nightlife settings where dehydration, overheating, and lack of sleep may lead to impairments in cognition and mood in the following days. When given in a clinical context these confounding variables can be controlled.”

The researchers analyzed data collected from 8 men and 6 women diagnosed with alcohol use disorder who had completed an 8-week psychotherapy course that included 10 sessions. During two extended psychotherapy sessions, the participants received 125 mg of MDMA followed by another dose of 62.5 mg of MDMA two hours later. Following these two dosing sessions, the participants remained in the treatment center overnight.

Mood was assessed once a day for seven days after each MDMA session. The participants maintained a positive mood overall and the researchers observed no significant fluctuations. “Instead of a comedown, participants actually maintained a positive mood in the days after dosing,” Aday told PsyPost. In addition, the patients were asked open-ended questions on non-dosing days, such as “How do you feel about MDMA-assisted sessions,” and responses the questions were generally positive.

The study also assessed sleep quality at baseline, during a 3-month follow up, and during a 6-month follow up. The researchers found that sleep quality tended to improve following the psychotherapy sessions. This is in line with other research, which has indicated that MDMA-assisted psychotherapy is linked to sleep improvements.

The findings highlight “that the context drugs are taken in can play an important role in their risks,” Aday told PsyPost. “By using pure MDMA on a limited number of occasions, not combining it with other substances, getting proper nutrition, and taking it early enough in the day to still get adequate sleep, risks can be reduced — although not eliminated.”

But the researchers cautioned that the findings can only be considered preliminary at this point.

“There are several major caveats to keep in mind,” Aday explained. “The main being this was a small sample of 14 participants; however, we were mandated to use a small sample because these results were a part of an exploratory study of MDMA therapy for treating alcohol use disorder. The results were promising, so future studies with larger sample sizes are underway.”

“Additionally, because this was an exploratory study, it was open label with no control group, meaning participants knew they were going to get MDMA and not placebo. Because of this, we cannot rule expectation and placebo effects. Again, future research will build upon this work to address these questions.”

Even if MDMA does not produce transient declines in mood and cognition, the use of the substance still includes some risks. “Because MDMA raises heart rate and blood pressure while people are under the drug, those with heart conditions may be at increased risk for a cardiac event,” Aday said. “Additionally, individuals can be highly suggestible and vulnerable while under the influence of the drug, so it is important to take it in a safe context with trusted individuals.”

The study, “Debunking the myth of ‘Blue Mondays’: No evidence of affect drop after taking clinical MDMA“, was authored by Ben Sessa, Jacob S Aday, Steve O’Brien, H Valerie Curran, Fiona Measham, Laurie Higbed, and David J Nutt.

RELATED

Neuroscientists just rewrote our understanding of psychedelics with a groundbreaking receptor-mapping study
ADHD

Young adults with different ADHD symptom profiles face distinct cannabis-related risks

September 3, 2025
Neuroscientists just rewrote our understanding of psychedelics with a groundbreaking receptor-mapping study
Ayahuasca

Neuroscientists just rewrote our understanding of psychedelics with a groundbreaking receptor-mapping study

September 1, 2025
New psychology research identifies a key factor behind support for harsh leaders
Cannabis

New research finds moderate cognitive impairments in heavy cannabis users

August 29, 2025
Surprising link found between aesthetic chills and political extremism
Anxiety

Single dose of psilocybin provides lasting relief from depression and anxiety in cancer patients

August 27, 2025
Scientists uncover biological pathway that could revolutionize anxiety treatment
MDMA

Psilocybin and MDMA may reset fear-related brain-immune signaling, scientists find

August 25, 2025
Does cannabidiol reduce worry severity or anxiety symptoms? New placebo-controlled study says no
Cannabis

Cannabidiol shows potential to reverse some neuropsychological effects of social stress

August 24, 2025
Stress-induced “fixated” eating patterns linked to dopamine disruption, study finds
Addiction

Dopamine-boosting drug enhances self-control and reduces drinking in people with alcohol use disorder

August 22, 2025
New research highlights potential of d-limonene in reducing THC-induced anxiety
Cannabis

Prenatal cannabis exposure linked to blunted brain response and psychotic-like symptoms in youth

August 22, 2025

STAY CONNECTED

LATEST

Researchers rushed to study the aftermath of the Trump shooting. Here’s what they found

What teddy bears reveal about comfort and care

Individuals experiencing faster biological aging are at increased risk of dementia

Young adults with different ADHD symptom profiles face distinct cannabis-related risks

Dark Triad personalities may be easier to scam than you’d think

Study finds women tend to favor sweet actions over sweet words in romantic partners

Study finds partisan hostility drives protest participation in the United States

Older obese individuals have a lower risk of dementia, but there is a big caveat

         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy